Rigel Pharmaceuticals, Inc.
RIGL
$41.50
-$0.49-1.17%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 267.92M | 203.08M | 179.28M | 157.37M | 130.20M |
| Total Other Revenue | -- | -- | -- | 100.00K | 100.00K |
| Total Revenue | 267.92M | 203.08M | 179.28M | 157.47M | 130.30M |
| Cost of Revenue | 42.98M | 41.28M | 36.49M | 32.04M | 25.58M |
| Gross Profit | 224.94M | 161.80M | 142.79M | 125.43M | 104.72M |
| SG&A Expenses | 113.54M | 112.33M | 113.06M | 110.39M | 108.20M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 163.33M | 159.15M | 155.09M | 147.97M | 139.32M |
| Operating Income | 104.59M | 43.93M | 24.19M | 9.50M | -9.02M |
| Income Before Tax | 99.14M | 38.12M | 18.37M | 3.88M | -14.23M |
| Income Tax Expenses | 1.32M | 946.00K | 881.00K | -- | -- |
| Earnings from Continuing Operations | 97.82 | 37.18 | 17.49 | 3.88 | -14.23 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 97.82M | 37.18M | 17.49M | 3.88M | -14.23M |
| EBIT | 104.59M | 43.93M | 24.19M | 9.50M | -9.02M |
| EBITDA | 107.01M | 46.36M | 26.42M | 11.42M | -7.42M |
| EPS Basic | 5.49 | 2.10 | 0.99 | 0.22 | -0.81 |
| Normalized Basic EPS | 3.48 | 1.35 | 0.65 | 0.14 | -0.51 |
| EPS Diluted | 5.41 | 2.07 | 0.97 | 0.21 | -0.82 |
| Normalized Diluted EPS | 3.43 | 1.33 | 0.64 | 0.14 | -0.51 |
| Average Basic Shares Outstanding | 70.94M | 70.60M | 70.32M | 70.11M | 69.94M |
| Average Diluted Shares Outstanding | 71.97M | 71.35M | 70.70M | 70.16M | 69.95M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |